SG Americas Securities
NVO

SG Americas Securities’s Novo Nordisk NVO Stock Holding History

SG Americas Securities’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,212,500
Closed -$2.3M – 3559
2025
Q4 		$2.3M Sell
2,212,500
-100,000
-4% -$5.11M ﹤0.01% 1445
2025
Q3 		$5.27M Buy
+2,312,500
New +$135M 0.02% 493

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

SG Americas Securities's NVO Position: Q2 2026 in Review

SG Americas Securities reduced its Novo Nordisk (NVO) stake by 7% in Q2 2026, selling an estimated $1.42M and leaving 439,134 shares worth $21.1M. The position accounts for 0.01% of the portfolio, ranked #585.

SG Americas Securities first reported a position in NVO in Q1 2015 and has held it in 34 quarters since. The position peaked at $132M in Q3 2025. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • SG Americas Securities held 439,134 shares of Novo Nordisk worth $21.1M as of Q2 2026.
  • SG Americas Securities sold 32,990 Novo Nordisk shares in Q2 2026, an estimated $1.42M.
  • Novo Nordisk made up 0.01% of SG Americas Securities's portfolio in Q2 2026, its #585 holding.
  • SG Americas Securities first reported a position in Novo Nordisk in Q1 2015 and has held it in 34 quarters since.
  • SG Americas Securities's Novo Nordisk position peaked at $132M in Q3 2025.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.